Sarepta gene therapy misses in Phase 3

The latest stories trending on MedCity News.

Editor's Pick

Top Story Sarepta Gene Therapy Misses in Phase 3; Prospects Now Rely on FDA Flexibility Sarepta Therapeutics' Duchenne muscular dystrophy gene therapy fell short of its main Phase 3 goal, but the firm contends the full body of evidence supports expanding the therapy's label to all patients who have the muscle-wasting disease. Analysts say prospects of the therapy, Elevidys, rest on FDA willingness to exercise flexibility it has already shown to rare disease drugmakers, including Sarepta. Sponsored Content Navigating Healthcare's Data Revolution: Priorities, Opportunities, and Challenges for Health Systems Presented by Arcadia Arcadia recently partnered with HIMSS Market Insights to survey executives, IT, technology, and clinical leaders. Here's what we found. Sponsored Content Heard at HLTH 2023: Quantum Health Chief Product Officer, Dan Shur likens healthcare navigation to Marco Polo, applying their insight into what will work and won't work with certain populations to improve engagement, ROI, financial outcomes.  Watch Now

Featured News

The New Era of Programmable Biology While legacy pharma companies battle in court with government agencies over how to address the costs that result from antiquated drug development paradigms, a growing cadre of compute-enabled life science companies are unlocking the nascent power of next-generation compute technologies to transform drug discovery and development. Eli Lilly Strikes $250M Deal to Add Gene-Editing Medicines for Cardio Conditions Eli Lilly is acquiring Beam Therapeutics' opt-in rights to three Verve Therapeutics gene-editing therapies for cardiovascular conditions. The deal comes four months after the pharmaceutical giant began a partnership on a preclinical Verve gene-editing therapy for a different target. MedCity Moves Podcast: Recent Hires, Layoffs & an Interview with Jeff Smith, CEO of Bamboo Health For the October episode, we discuss some recent executive hires and departures occurring in the healthcare sector, as well as layoffs affecting the industry. We also hear from Jeff Smith, who became the new CEO of Bamboo Health this month. 48 Senators Urge Biden Administration To Mandate Coverage of OTC Contraceptives Several senators wrote a letter to the Biden Administration asking for action that ensures coverage of over-the-counter birth control without the need for a prescription. The letter was led by Senators Patty Murray (D-Washington), Tammy Baldwin (D-Wisconsin), Bernie Sanders (I-Vermont) and Ron Wyden (D-Oregon).

Resources

MedCity FemFwd Podcast: SCAN Inspired With Nancy Monk, Chief Operations Officer of SCAN Health Plan MedCity FemFwd, a podcast dedicated to discussing the breakthroughs and challenges in women's health, is back with another episode. This time, we are joined by Nancy Monk, chief operations officer of Medicare Advantage insurer SCAN Health Plan, to talk about the company's recent launch of SCAN Inspired, a Medicare Advantage plan designed for women.  Listen Now

MedCity News • PO Box 901 • New York, NY unsubscribe